An Open-label, Non-randomized Phase I Investigation of Human ADME (Absorption, Distribution, Metabolism and Excretion) and Absolute Oral Bioavailability of BI 907828 in Patients With Advanced Solid Tumours
Latest Information Update: 24 Jan 2025
At a glance
- Drugs Brigimadlin (Primary) ; Brigimadlin (Primary) ; Brigimadlin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 22 Jan 2025 Status changed from active, no longer recruiting to completed.
- 27 Sep 2024 Planned End Date changed from 13 Dec 2024 to 15 Jan 2025.
- 27 May 2024 Planned End Date changed from 3 Oct 2024 to 13 Dec 2024.